Avanos Medical, Inc. reported a net sales increase of 8.8% for the first quarter of 2026, reaching $182.2 million compared to $167.5 million in the same period of 2025. The company's gross profit for the quarter was $94.2 million, resulting in a gross margin of 51.7%. However, operating income decreased to $8.9 million from $10.3 million year-over-year, primarily due to increased costs associated with tariffs and restructuring initiatives. Net income for the quarter was $5.1 million, down from $6.6 million in the prior year, leading to earnings per share of $0.11, compared to $0.14 in the same period last year.
The company experienced significant changes in its financial performance, particularly in its Specialty Nutrition Systems (SNS) segment, which saw a 22.7% increase in net sales to $124.0 million, driven by strong demand for enteral feeding products and neonate solutions. Conversely, the Pain Management and Recovery (PM&R) segment reported flat sales at $56.3 million, with a notable decline in surgical pain and recovery product sales. The overall increase in sales was offset by rising costs, including a 13.5% increase in the cost of products sold, which totaled $88.0 million.
Strategically, Avanos completed the acquisition of Nexus Medical in September 2025 for $27 million, with potential additional payments based on future sales performance. This acquisition is expected to enhance Avanos's SNS portfolio, particularly in high-acuity settings. The company also initiated a restructuring plan following the divestiture of its Respiratory Health business, which is projected to incur up to $10 million in costs, primarily for employee severance and benefits. In the first quarter of 2026, restructuring costs amounted to $1.8 million, a decrease from $3.1 million in the same quarter of 2025.
Operationally, Avanos reported a decrease in cash and cash equivalents to $65.6 million as of March 31, 2026, down from $89.8 million at the end of 2025. The company’s total liabilities decreased to $268.0 million from $295.5 million, reflecting a reduction in accrued expenses and current liabilities. The employee headcount remained stable, with no significant changes reported. The company continues to face challenges related to tariffs and supply chain disruptions, which could impact future performance.
Looking ahead, Avanos remains focused on executing its strategic initiatives, including the integration of Nexus Medical and the ongoing restructuring plan. The company anticipates that these efforts will lead to improved operational efficiency and cost savings in the long term. However, management cautioned that various risks, including economic conditions and competitive pressures, could affect future results. The company is also preparing for a pending merger with affiliates of American Industrial Partners, which, if completed, will result in Avanos becoming a privately held entity.
About AVANOS MEDICAL, INC.
Avanos Medical, Inc. develops, manufactures, and markets medical devices focused on Digestive Health and Pain Management and Recovery. Its key products include enteral feeding tubes, neonatal feeding solutions, and non-opioid pain relief therapies such as surgical pain pumps and radiofrequency ablation devices. Serving hospitals and healthcare providers globally, Avanos emphasizes clinically effective, reliable solutions that improve patient outcomes and reduce healthcare costs through a broad distribution network and strong customer engagement.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.